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This study examined the relationship between the severity of acute human immunodeficiency
virus type 1 (HIV-1) illness and disease progression and death. The population included 218 patients
with acute HIV-1 illness and 41 asymptomatic patients who underwent HIV-1 seroconversion; the
patients were followed up prospectively. We analyzed progression to Centers for Disease Control
and Prevention clinical categories B and C (AIDS-defining conditions) and death according to an
additive clinical score (CS) based on six predictive clinical features at the time of acute HIV-1
infection. Compared with patients with a CS of 0 (asymptomatic patients), those with a CS of
3–4 and 5–6 had faster progression to category B disease (adjusted hazard ratio [HR], 1.39; 95%
confidence interval [CI], 1.01–1.92; and HR, 1.80; 95% CI, 1.34–2.40; respectively); those with a
CS of 5–6 had faster progression to category C disease (HR, 1.37; 95% CI, 1.01–1.89) and death
(HR, 2.05; 95% CI, 1.27–3.32). Thus, the number of symptoms and signs at the time of acute
HIV-1 illness affects disease progression and survival, even in symptomatic patients who have
undergone seroconversion.
We were thus interested in exploring whether a score repre-The duration and the severity of acute HIV-1 illness have
been associated with a more rapid disease progression [1–6] senting a gradient of clinical severity of acute HIV-1 disease
could identify patients at higher risk of progression. More spe-and were associated with shorter survival in one study [6].
However, the usual classification of patients who seroconverted cifically, the objectives of this study were to identify symptoms
and signs reported at the time of acute HIV-1 infection thatas symptomatic or asymptomatic does not adequately explore
the predictive value of different symptoms and signs in symp- are associated with rapid progression to the first clinical event
of category B and to estimate the hazard ratio (HR) for AIDS,tomatic patients who seroconverted.
According to the Centers of Disease Control and Prevention defined as the first clinical event of category C and death in
terms of the number of symptoms and signs at the time of(CDC) [7], the first clinical event of category B is an HIV-1-
related event, mostly consisting of oral lesions, that is associ- acute HIV-1 infection.
ated with the subsequent risk of an event of category C (AIDS-
defining conditions) and death [8–10].
Methods
Study Population
Received 5 June 1997; revised 21 August 1997.
We investigated 259 newly HIV-1-infected persons enrolledThis work was presented in part at the 11th International Conference on
AIDS held on 7–12 July 1996 in Vancouver, British Columbia, Canada, and in four prospective studies of the incidence of HIV-1 disease
at the 8th European Congress of Clinical Microbiology and Infectious Diseases that were performed between 1985 and 1994 and had similarheld on 25–28 May 1997 in Lausanne, Switzerland.
standardized biannual follow-ups. Two cohorts were coordi-Informed consent was obtained from all patients enrolled in the different
cohorts. nated by the National Centre in HIV Epidemiology and Clinical
Financial support: P.V. was supported by the Swiss Foundation for Scientific Research in Sydney, New South Wales, Australia, and twoResearch (823B-033270), the University of New South Wales (Sydney, New
cohorts were coordinated in Geneva. The Australian cohortsSouth Wales, Australia), and the Canadian HIV Trials Network–Quebec Re-
gion. The National Centre in HIV Epidemiology and Clinical Research is involved 171 patients, mostly homosexual men at risk of HIV
supported by the Australian National Council on AIDS through the Common- infection, who have been extensively described elsewherewealth AIDS Research Grants Committee.
[11–13]. The European cohorts consisted of 88 patients of bothReprints or correspondence: Dr. Philippe Vanhems, Centre Hospitalier Lyon-
Sud, Unite´ d’Hygiene, Epidemiologie et Information Me´dicale, Pavillon 1 M, genders who had various risk factors for acquisition of HIV
69495 Pierre-Be´nite, Cedex, France. infection and were enrolled in the Swiss HIV Cohort Study in
Clinical Infectious Diseases 1998;26:323–9 Geneva [14] or in a placebo-controlled trial of zidovudine dur-
q 1998 by The University of Chicago. All rights reserved.
1058–4838/98/2602–0010$03.00 ing primary HIV-1 infection [15].
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Biological and Clinical Inclusion Criteria screening test (criterion 3). Survival time to category B disease,
category C disease, and HIV-1-related death was measured
Symptomatic patients. Acute HIV-1 infection in 218 pa-
from time 0 to each outcome or censored at the date that the
tients was confirmed by the following criteria: (1) the presence
patient was last confirmed to be alive and not to have reached
of p24 antigen in blood with negative or indeterminate antibod-
any end point at study termination (1 June 1995). The survival
ies to HIV by ELISA (135 patients [62%]); (2) two bands on
curves did not differ by time 0 definitions among patients with
a western blot, one of which corresponded to the env gene
acute HIV-1 illness.
(glycoprotein [gp] 160, gp 120, or gp 41) with negative or
Time to category B disease was estimated by the Kaplan-
indeterminate antibodies to HIV by ELISA (18 [8%]); or (3)
Meier method and compared by the generalized Wilcoxon test
a negative HIV-1 ELISA followed by a positive HIV-1 ELISA
(which gives more weight to early events [17]) after stratifica-
within 1 year (mean, 140.0 days) (65 [30%]). The diagnosis
tion of the presence or absence of each symptom and sign at
of HIV-1 infection was confirmed by western blotting of fol-
the time of acute HIV-1 illness. Proportional hazards models
low-up blood samples from all patients included in this study.
[18] were fitted to estimate the unadjusted and adjusted HR of
Their symptoms and signs have been extensively reported [13],
category B disease after selection of symptoms and signs from
and only those occurring in 10% of patients were analyzed
the univariate analysis and assumption of risk proportionality.
here.
The multivariate analyses were always adjusted by center (Ge-
Asymptomatic patients. Forty-one asymptomatic patients
neva vs. Sydney) as a confounder to account for variations that
had a negative HIV-1 ELISA followed by a positive HIV-1
could have occurred between the centers, such as the sex ratio,
ELISA within 1 year (mean, 180.0 days) (criterion 3). They
the proportion of patients per risk factor for HIV-1 infection,
were enrolled in the cohorts at the same time as the symptom-
and potential differences of frequency of symptoms and signs
atic patients, and their asymptomatic status was assessed ac-
reported.
cording to self-report and was confirmed by examination of
To explore a potential dose-effect relationship between the
each patient’s medical record.
number of symptoms and signs and disease progression, we
End points. The end points considered in this study were
created an additive clinical score (CS) with variables individu-
clinical events exclusively. The clinical end points were the
ally associated with progression to category B disease at a
first clinical event of category B (AIDS excluded), the first
statistical level of£.10 that were determined by the generalized
clinical event of category C (or an AIDS-defining condition),
Wilcoxon test. (Pharyngitis was included because of its high
as defined by the 1992 criteria of the CDC [7], and death. The
prevalence and a P value of .11.) The prognostic value of the
diagnoses and dates of HIV-1-related events were confirmed
symptoms and signs included in the CS was also confirmed by
by examination of medical records and were also cross-checked
univariate proportional hazards models. The CS consisted of
against the database of the Swiss HIV Cohort Study in Geneva
the sum of values for each variable (0 for absent or not reported
and the AIDS registry of the National Centre in HIV Epidemi-
and 1 for present). The adjusted HR for category B disease,
ology and Clinical Research in Sydney [16]. We did not use
category C disease, and death by CS was estimated by using
the CD4 cell count as a diagnostic criterion for category B and
the proportional hazards models with asymptomatic patients as
category C outcomes. Because some clinical features of acute
the reference group (CS, 0; HR, 1.0).
HIV-1 infection could be similar to clinical end points (i.e.,
To estimate a synergistic effect on disease progression be-
oral candidiasis or diarrhea), we confirmed that all acute signs
tween the presence of clinical features and their duration, we
and symptoms used in the prognostic analysis (see below) had
tested the interaction term (CS 1 duration of symptoms) by
resolved at the end of the acute stage of HIV-1 infection. HIV-
using the proportional hazards model.
1-related deaths were confirmed from medical records and the
All P values were two-sided and considered significant
autopsy reports if available.
if .05.
Statistical Analysis Results
The patients were mostly men (93%), and the probable modeDisease progression was defined by occurrence of the first
category B disease, the first category C disease, and HIV-1- of HIV-1 infection was homosexual or bisexual contact in 79%
of cases. The mean age of the patients { SD was 31.7 { 7.7related death. Eight patients who died of causes not considered
HIV-1-related (4 overdoses, 2 suicides, 1 acute myocardial years, and the mean duration of acute HIV-1 illness { SD was
25.1 { 22.3 days. The conditions of 81 (31%), 63 (24%), andinfarction, and 1 murder) were censored for survival analysis
at the time of death. 54 (21%) of the patients progressed to category B disease,
category C disease, and death, respectively; these categoriesSurvival analysis started from time 0, defined as the date of
documented acute HIV-1 infection (criterion 1 or 2) or the were not mutually exclusive. The median follow-up for the
entire cohort was 3.2 years (range, 0.12–10.6 years). The me-midpoint between the last negative and the first positive HIV-1
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dian times to category B disease, category C disease, and death 0.98–1.05), duration of acute HIV-1 illness (0.99; 95% CI,
0.97–1.00), year of infection (1.19; 95% CI, 0.73–1.92), zido-were 6.1 years (95% CI, 5.1–7.1), 7.3 years (95% CI, 6.7–
8.0), and 8.6 years (95% CI, 7.3–9.8), respectively. vudine administration at the time of acute HIV-1 infection
(0.62; 95% CI, 0.31–1.27), and other symptoms and signs.The median time of progression to category B disease ac-
cording to symptoms and signs at the time of acute HIV-1 Lethargy was also associated with progression to category B
disease, with an adjusted HR of 1.84 (95% CI, 1.02–3.32;infection is shown in table 1. Oral candidiasis, which occurred
in 37 patients (14%), was the strongest predictor, with a median P  .04).
The symptoms and signs reported in table 1 were candidatetime to disease of 3.9 years compared with 6.6 years for patients
without this condition (P  .0002) and with an adjusted HR predictors for the additive CS. The most parsimoniously dis-
criminating CS included fever (temperature,⁄387C), skin rash,of 2.88 (95% CI, 1.47–5.63; P  .002); the HR was adjusted
for center (0.50; 95% CI, 0.30–0.90), age (1.01; 95% CI, lethargy, oral candidiasis, pharyngitis or sore throat, and diar-
rhea. The univariate HRs for the symptoms and signs of the
first category B disease were as follows: fever, 1.86 (95% CI,
1.18–2.95); skin rash, 2.0 (95% CI, 1.28–3.12); lethargy, 2.04Table 1. Symptoms and signs at the time of acute HIV-1 illness in
(95% CI, 1.30–3.21); oral candidiasis, 2.60 (95% CI, 1.48–259 patients that were associated with the first category B disease.
4.60); pharyngitis or sore throat, 1.44 (95% CI, 0.91–2.25);
Median time† and diarrhea, 1.38 (95% CI, 0.83–2.31). The CS ranged from
(y) to the 0 to 6 and was stratified as 0, 1–2, 3–4, and 5–6 (from absence
first category
to high severity). The adjusted HR for each outcome by CSNo. of B disease P
strata is shown in table 2. Patients with a CS of moderate (3–Symptom or sign* patients (95% CI) value‡
4) to high (5–6) severity had a higher risk of progression to
Diarrhea category B disease, but only patients with a CS of high severity
No 209 6.4 (5.7–7.0) had a higher risk of progression to category C disease and
Yes 50 4.6 (3.0–6.1) .05
death.Abdominal pain
The risk of progression to category B disease, category CNo 217 6.2 (5.3–7.0)
Yes 42 4.2 (1.1–7.2) .01 disease, and death at 3, 5, and 7 years per CS strata is reported
Fever (temperature, in table 3.
⁄387C) For our study population, the interaction term (CS1 duration
No 91 6.8 (5.8–7.7)
of symptoms) was not statistically associated with a fasterYes 168 5.1 (4.0–6.2) .03
progression to the first category B disease (HR, 0.98; 95% CI,Night sweats
No 211 6.1 (5.7–6.7) 0.95–1.02), the first category C disease (HR, 1.0; 95% CI,
Yes 48 4.3 (3.0–5.7) .05 0.95–1.05), or death (HR, 0.98; 95% CI, 0.92–1.05).
Lethargy
No 116 7.0 (6.1–8.0)
Yes 143 5.1 (4.2–6.0) .008 Discussion
Skin rash
No 136 6.8 (5.8–7.8) Our aim was to investigate the association between the type,
Yes 123 4.6 (3.2–5.9) .004 number, and duration of symptoms and signs reported at the
Pharyngitis or sore throat time of acute HIV-1 illness and disease progression and sur-
No 163 6.6 (5.6–7.2)
vival.Yes 96 5.1 (4.6–5.6) .11
Specific features of acute HIV-1 illness previously associatedOdynophagia
No 198 6.2 (5.6–6.7) with disease progression were rash and fever [2, 5], possibly
Yes 61 5.1 (3.1–7.1) .01 because these features were easy to detect and also because
Oral candidiasis these studies were done early in the AIDS epidemic (when
No 222 6.6 (6.0–7.1)
descriptions of acute HIV-1 illness were less detailed). TheseYes 37 3.9 (2.2–5.5) .0002
findings were not confirmed in the present study because ofNone of the above
symptoms 52 7.2 (6.3–8.1) the high correlation between symptoms; we found that oral
One or more of the above candidiasis was the strongest predictor of disease progression
symptoms 207 5.5 (4.5–6.4) .04 after adjustment.
Our results suggest a dose-response relationship between the* The symptoms and signs reported here were listed extensively in [13]. In
the present study, the symptoms and signs with the highest association with number of symptoms and signs at the time of acute infection
the first category B disease are reported (results for other symptoms and signs and the prognosis, since the highest rate of progression and
are available from the corresponding author).
death was found among patients with the highest CS. A signifi-† Kaplan-Meier method.
‡ Generalized Wilcoxon test. cant HR for category B disease was observed for those patients
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Table 2. Adjusted HRs for category B disease, category C disease, and death by clinical score of the severity of acute HIV-1 disease in 259
patients.
HR of category B disease HR of category C disease HR of death
Clinical No. of
score Severity patients HR*† 95% CI P value HR‡ 95% CI P value HR§ 95% CI P value
0 52 1.00 1.00 1.00
1–2 Low 77 1.26 0.66–2.38 .47 0.95 0.47–1.89 .98 1.34 0.57–3.15 .49
3–4 Moderate 102 1.39 1.01–1.92 .03 1.10 0.78–1.55 .58 1.34 0.93–1.93 .11
5–6 High 28 1.80 1.34–2.40 .0001 1.37 1.01–1.89 .04 2.05 1.27–3.32 .003
NOTE. HR  hazard ratio.
* Each stratum was compared with the reference stratum (clinical score  0).
† The value of the likelihood was (02 log likelihood) 712.078 with 5 df (P  .001). The model was adjusted for center (Geneva vs. Sydney, New South Wales,
Australia) (HR, 0.5; 95% CI, 0.30–0.94); age as a continuous variable (HR, 1.0; 95% CI, 0.97–1.03); year of infection stratified as until 1987 (n  86), from
1988 to 1991 (n  65), and from 1992 (n  108) (HR, 1.05; 95% CI, 0.68–1.64); and zidovudine administration at the time of acute HIV-1 disease (n  68)
(HR, 0.63; 95% CI, 0.32–1.24).
‡ The value of the likelihood was (02 log likelihood) 488.120 with 5 df (P  .0001). The model was adjusted for center (HR, 0.60; 95% CI, 0.21–1.50), age
(HR, 1.0; 95% CI, 0.97–1.04), year of infection (HR, 1.63; 95% CI, 0.85–3.10), and zidovudine administration before category C disease (n  43) (HR, 7.1;
95% CI, 3.9–12.8).
§ The value of the likelihood was (02 log likelihood) 383.328 with 6 df (P  .0001). The model was adjusted for center (HR, 0.58; 95% CI, 0.13–2.58), age
(HR, 1.01; 95% CI, 0.97–1.06), year of infection (HR, 0.92; 95% CI, 0.38–2.21), zidovudine use at any time (n  89) (HR, 1.34; 95% CI, 0.73–2.45), and use
of secondary prophylaxis for Pneumocystis carinii pneumonia (n  15) (HR, 4.89; 95% CI, 2.40–9.97).
with at least three symptoms or signs. For category C disease retroviral therapy (which could decrease the prognostic impact
of the severity of acute HIV-1 illness).and death, a significant HR was observed for those patients
with at least five symptoms or signs, thus suggesting that the The pathogenetic factors that govern the severity and dura-
tion of acute illness at the time of seroconversion are unclear.most severe acute illnesses only predict advanced disease. The
HR observed between patients in extreme categories (0 vs. A severe acute illness could be due to infection with HIV that
escapes CD8/ cell control and destroys CD4/ cells because of5–6) was less than HRs observed in previous studies [1, 2,
4, 5]. This finding could be explained by a different study a high level of replication [19, 20]. The CD4/ cell count per-
formed within 2 weeks of infection in 112 of our patients andpopulation, but it could also be explained by previous investiga-
tors having considered all symptomatic patients in the same the serum level of HIV RNA, determined for 30 patients (me-
dian time from the onset of acute illness, 17.0 days), bothgroup [4, 5] and by different adjustments on confounders. Per-
haps most important, 47% of our patients were infected after correlated with the CS (CD4/ cell count: r  0.20, P  .03;
HIV RNA serum level: r  .44, P  .01). These observations1992, which means that they were more likely to receive anti-
Table 3. Risk of progression to category B disease, category C disease, and death by clinical score for 259 HIV-1-infected patients.
Category B disease Category C disease Death
Median Median Median
Percent of patients with disease Percent of patients with disease Percent of patients who diedtime* to time* to time* to
Clinical disease disease death in
presentation in y At 3 y At 5 y At 7 y P in y At 3 y At 5 y At 7 y P y (95% At 3 y At 5 y At 7 y P
(no. of patients) (95% CI) (95% CI) (95% CI) (95% CI) value† (95% CI) (95% CI) (95% CI) (95% CI) value† CI) (95% CI) (95% CI) (95% CI) value†
Asymptomatic (52) 7.1 11 23 49 7.6 2 18 37 8.2 0 9 17
(6.3–8.1) (10–12) (10–35) (31–68) (6.5–8.7) (1–6) (4–27) (20–55) (7.9–8.6) (1–18) (2–30)
CS of 1–2 (77) 6.1 15 34 56 7.3 12 31 35 3 13 37
(5.2–7.0) (6–24) (20–48) (39–74) (7.0–9.2) (4–21) (16–46) (19–50) ND‡ (1–9) (2–24) (19–55)
CS of 3–4 (102) 6.1 13 45 74 6.7 5 37 50 7.6 3 13 42
(4.3–7.8) (6–20) (28–62) (54–93) (3.9–9.5) (1–10) (20–54) (31–69) (5.7–9.5) (1–8) (2–24) (23–61)
CS of 5–6 (28) 2.8 52 81 100 4.4 26 54 85 5.5 13 23 77
(1.3–4.4) (27–78) (58–96) (58–100) .008 (3.2–5.5) (4–29) (26–82) (58–100) .03 (4.5–6.4) (4–30) (2–46) (40–86) .03
NOTE. CS  clinical score; ND  not determined.
* Cumulative progression to category B disease, category C disease, and death was determined by the Kaplan-Meier survival analysis.
† Generalized Wilcoxon test used to compare the survival distributions by clinical presentation.
‡ Data not determined because 50% of patients presented with the event during the follow-up.
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complement studies that reported a significant predictive value of acute HIV-1 illness was 12.0 days (range, 4–62 days), and
the median time from the onset of acute HIV-1 illness to cate-for a low CD4/ cell count [5, 20] and a high viral load at
3–6 months following seroconversion [21]. Other factors, such gory B disease was 1,281 days (range, 60–3,259 days). Two
patients had progression to category B disease within 80 days.as host genetics [22–24], HIV phenotype [25], cytotoxic im-
mune response [26, 27], and HIV-1 dynamics [28], could affect In both cases, the diagnosis of category B disease was oral
candidiasis, and in one case, oral candidiasis was also reportedthe clinical expression of seroconversion and the subsequent
prognosis. The CD4/ cell count before seroconversion has been at the time of acute HIV-1 infection. In this patient, oral candi-
diasis resolved by the 8th day after the onset of acute HIV-1associated with the rate of disease progression [29]; in this
study, patients with high CD4/ cell counts before seroconver- infection.
Fifty-five (68%) of 81 patients presented with oral candidia-sion tended to have high CD4/ cell counts afterward, and their
conditions progressed more slowly. Further investigations sis as a category B disease. Of these 81 patients, nine presented
with oral candidiasis at the time of acute HIV-1 infection. Weshould explore in detail the effect of immunologic background
on the spectrum of acute HIV-1 illness. did not observe a statistical association between oral candidiasis
at the time of acute HIV-1 infection and oral candidiasis as aThe oral cavity is an important target of HIV-1 infection. A
diagnosis of acute HIV-1 infection is suggested by oral candidi- category B disease (P  .46). Similar results were observed
for the presence of esophageal candidiasis as a category Casis and/or sore throat or pharyngitis associated with a skin rash
and/or fever. Oral candidasis is a strong predictor of disease disease and the presence of oral candidiasis at the time of acute
HIV-1 infection (P  .70).progression. Finally, the first category B disease occurred in
the mouth in 64 patients (79%) (oral candidiasis, 55 patients; The survival analyses could be biased because the time 0
determination was less accurate for the asymptomatic patientshairy leukoplakia, nine patients).
We must consider some limitations of this study. The results who underwent seroconversion. Symptomatic patients who un-
derwent seroconversion, because of their symptoms, had ancannot be generalized to the whole population newly infected
by HIV-1 because enrollment in the study cohorts was based incentive to be retested sooner than they would have been
had they remained asymptomatic, thus decreasing the averageon a voluntary decision. In addition, living far away from large
cities and/or university medical centers can be a factor in the interval between the last negative test and the first positive test.
To estimate this bias, we conducted a second survival analysis;lack of recruitment of other symptomatic patients who have
undergone HIV-1 seroconversion. Persons not considering asymptomatic patients were retested an average of 180 days
after the previous (HIV-1-negative) test, and the symptomaticthemselves at risk of HIV-1 infection or less aware of their
health status could be also underrepresented in the study popu- patients were retested an average of 140 days after the previous
(HIV-1-negative) test. We assumed that if they had been symp-lation. Thus, these findings can be most appropriately compared
with results provided for similar cohorts. tomatic, the asymptomatic patients would have been tested an
average of 40 days sooner than they in fact were. Therefore,A limitation of our study is the heterogeneous population,
since the patients were enrolled in different prospective studies we added 40 days to the follow-up of 65 symptomatic patients
included on the basis of criterion 3. The results obtained afterwith different inclusion criteria. We used complementary
means to reduce this bias. A standardized form for collection this survival calculation did not differ from the results reported
in table 3 (data not shown). This result is in accord with theof data was used at both centers. The standardized forms from
each cohort study were double-checked with all private and findings of Brookmeyer and Gail [30]; these investigators re-
ported that the bias resulting from midpoint imputation in thehospital medical records available (231 of 259) by the same
investigator (P.V.). However, diarrhea and pharyngitis were case of doubly censured data is negligible when the period
during which seroconversion occurred is 1 year, which wasreported more frequently in Sydney (P  .05), and fever was
reported more frequently in Geneva (P  .05). These differ- provided for in criterion 3.
Severely symptomatic patients who underwent seroconver-ences could be related to the medical examination, the charac-
teristics of the study population, a different presentation of sion may have been followed up more closely, thus leading to
earlier detection of outcomes (detection bias). This bias couldacute HIV-1 illness by location, or a recall and/or misclassifi-
cation bias. Nevertheless, all multivariate analyses were ad- lead to an overestimate of the difference between the sickest
patients (CS  5–6) and those with mild disease (CS  0 orjusted for the center (Geneva vs. Sydney) to account for these
differences. CS  1–2). This bias is difficult to control for because even
with a standardized 6-month follow-up, any complication oc-In some cases, the patients presented with clinical features
that could also be considered as a clinical end point (see under curring between medical examinations could be more accu-
rately reported for severe events that required hospitalization.Methods). This could be the case for oral candidiasis and diar-
rhea at the time of acute HIV-1 infection, which are also defin- We do not know the quantity of medical resources used be-
tween each assessment, which could help estimate the likeli-ing clinical events of category B disease. For the 81 patients
who presented with a category B disease, the median duration hood of a detection bias having affected our results. Neverthe-
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Finally, we limited the study to the symptoms and signs AIDS in HIV-1 seroconverters. AIDS 1993;7:51–7.
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8. Rabeneck L, Crane MM, Risser JMH, Lacke CE, Wray NP. A simplesymptoms possible.
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sion to oral candidiasis or hairy leukoplakia among homosexual anding acute HIV-1 infection was the sign most strongly associated
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10. Greenspan D, Greenspan JS, Overby G, et al. Risk factors for rapid pro-
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death. The CS that we used could be a helpful clinical tool in J Acquir Immune Defic Syndr 1991;4:652–8.
11. Sydney AIDS Study Group. The Sydney AIDS project. Med J Aust 1984;determining prognosis and in deciding about the early use of
141:569–73.therapy when viral load determinations are not available. Pa-
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